stavudine has been researched along with Cardiovascular Diseases in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bjørge, NID; Elming, MB; Fuchs, A; Gelpi, M; Knudsen, AD; Kofoed, KF; Krebs-Demmer, L; Kühl, JT; Køber, L; Lebech, AM; Lundgren, J; Nielsen, SD; Nordestgaard, BG; Sigvardsen, PE | 1 |
| Barth, RE; Chersich, MF; Grobbee, DE; Kambugu, A; Klipstein-Grobusch, K; Kumarasamy, N; Lalla-Edward, ST; Moorhouse, MA; Venter, WD; Vos, AG; Zuithoff, P | 1 |
| Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
| Cournil, A; Diouf, A | 1 |
| Bratt, GA; Eriksson, LE; Nilsson Schönnesson, L | 1 |
| Dehayem, MY; Echouffo-Tcheugui, JB; Ekali, LG; Fezeu, L; Hayes, L; Johnstone, LK; Kouanfack, C; Nouthe, B; Sobngwi, E; Unwin, NC | 1 |
| Adami, M; Boillat-Blanco, N; Cavassini, M; Daou, S; Darling, KE; Elzi, L; Fehr, J; Osih, R; Strahm, C; Taffe, P; Wandeler, G | 1 |
| Coupal, L; Gilmore, N; Grover, SA; Mukherjee, J | 1 |
| Nolan, D | 1 |
| Antela, A; Domingo, P; Llibre, JM; Miralles, C; Moreno, S; Palacios, R; Pérez-Elías, MJ; Sánchez-de la Rosa, R; Santos, J | 1 |
| Nelson, M; Waters, L | 1 |
2 review(s) available for stavudine and Cardiovascular Diseases
| Article | Year |
|---|---|
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Metabolic Syndrome; Nevirapine; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Zidovudine | 2005 |
Long-term complications of antiretroviral therapy: lipoatrophy.
Topics: Anti-HIV Agents; Body Image; Cardiovascular Diseases; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Stavudine; Time Factors; Zidovudine | 2007 |
2 trial(s) available for stavudine and Cardiovascular Diseases
| Article | Year |
|---|---|
Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Cardiovascular Diseases; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; India; Insulin Resistance; Lipids; Male; Risk Factors; South Africa; Stavudine; Tenofovir; Uganda | 2018 |
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Female; HIV Infections; Humans; Hyperlipidemias; Lamivudine; Life Expectancy; Male; Markov Chains; Middle Aged; Nelfinavir; Oligopeptides; Pyridines; Risk Factors; Stavudine | 2005 |
7 other study(ies) available for stavudine and Cardiovascular Diseases
| Article | Year |
|---|---|
Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Cardiovascular Diseases; Denmark; Didanosine; Female; Healthy Volunteers; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Pericardium; Risk Factors; Stavudine; Viral Load | 2020 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
[Prevalence of metabolic complications after 10 years of antiretroviral treatment in Senegal].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Diabetes Mellitus; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lipodystrophy; Male; Metabolic Diseases; Middle Aged; Senegal; Stavudine | 2014 |
Lipoatrophy of the footpad in HIV-treated patients is associated with increased PAI-1.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Atrophy; Cardiovascular Diseases; Cross-Sectional Studies; Didanosine; Foot; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prevalence; Risk Factors; Stavudine | 2011 |
Fasting blood glucose and insulin sensitivity are unaffected by HAART duration in Cameroonians receiving first-line antiretroviral treatment.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Blood Pressure; Body Fat Distribution; Cameroon; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fasting; Female; Health Services Accessibility; HIV Infections; Humans; Insulin Resistance; Lipids; Male; Stavudine; Time Factors | 2013 |
Impact of recommendation updates in well-controlled patients on nonrecommended antiretroviral therapies: the Swiss HIV cohort study.
Topics: Adult; Cardiovascular Diseases; Chi-Square Distribution; Cholesterol; Diabetes Complications; Didanosine; Drug Therapy, Combination; Female; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Retrospective Studies; Reverse Transcriptase Inhibitors; Sex Factors; Statistics, Nonparametric; Stavudine; Switzerland; Viral Load | 2013 |
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Risk Factors; Stavudine; Tenofovir | 2006 |